Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways
The Journal of Clinical Pharmacology · 2025-11 · 65 (11) · 1420-1432
DOI: 10.1002/jcph.70061 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 15.06.2025. Verfasst von Priyanka Arora und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, CA, USA. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Heterocyclic Compounds, 4 or More Rings, Cytochrome P-450 CYP3A, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK) and safety of bictegravir (administered alone or as bictegravir/emtricitabine/tenofovir alafenamide fumarate [TAF]) were assessed when co‐administered with inducers (rifampin, rifabutin, and rifapentine) or inhibitors (atazanavir ± cobicistat, darunavir + cobicistat, and voriconazole) of cytochrome P450 3A4 (CYP3A4), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), and/or P‐glycoprotein (P‐gp). PK parameters were compared using analysis of variance to calculate geometric least‐square mean ratios and 90% confidence intervals. Overall, 172 participants were enrolled. CYP3A4 inhibition (voriconazole) moderately increased bictegravir exposure (61% increase in area under the concentration‐time curve extrapolated to infinity [AUC inf ]), whereas dual CYP3A4 and UGT1A1 inhibition (atazanavir) led to a 315% increase in AUC inf . P‐gp inhibition had a minimal effect on bictegravir exposure. Induction of CYP3A4, UGT1A1, and/or P‐gp by rifampin, rifabutin, and rifapentine led to decreases in bictegravir exposure and/or trough concentration (C trough ). Bictegravir and bictegravir/emtricitabine/TAF were well tolerated alone and in combination with other drugs. Inhibition of CYP3A4 or UGT1A1 alone is unlikely to cause clinically meaningful changes in bictegravir exposure; only potent inhibitors of both pathways are expected to significantly affect bictegravir PK. Induction of CYP3A4 with/without UGT1A1 significantly influenced bictegravir PK, although C trough remained above the protein‐adjusted 95% effective concentration. These findings should be considered when co‐administering medications with bictegravir.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, CA, USA.
ORCID-Profile: Priyanka Arora, Hui Liu, Jason T Hindman, Dhananjay D Marathe
Zitieren
APA
Arora, P., Liu, H., Ling, J., Hindman, J. T., & Marathe, D. D. (2025). Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways. The Journal of Clinical Pharmacology, 65(11), 1420-1432. https://doi.org/10.1002/jcph.70061
Vancouver
Arora P, Liu H, Ling J, Hindman JT, Marathe DD. Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways. The Journal of Clinical Pharmacology. 2025;65(11):1420-1432. doi:10.1002/jcph.70061
BibTeX
@article{Arora2025,
author = {Arora, Priyanka and Liu, Hui and Ling, John and Hindman, Jason T and Marathe, Dhananjay D},
title = {Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
volume = {65},
number = {11},
pages = {1420--1432},
doi = {10.1002/jcph.70061}
}
EUVIMED